Tag: targeted therapy

Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads

Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion

Based on a recent analysis published earlier this years DataM Intelligence predict that the market size of the for Antibody-drug Conjugates (ADC) valued at around US $11.9 billion in 2024, is projected to surge past US $30.4 billion by 2033, expanding at a robust CAGR of 11.2% (2025–2033).

In a statement Pfizer confirmed that it has discontinued the development of felmetatug vedotin (also known as PF-08046048 or SGN-B7H4V; see Drugmap).

The US Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications from Cambridge, Massachusetts-based biotech Pyxis Oncology, allowing the company to...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

Tumors often comprise groups of cancer cells that show differential drug sensitivities. This is one of the reasons that initially effective treatments usually do...

Currently used anticancer drugs are highly cytotoxic and therapies are often associated with multiple, severe adverse events. For decades drug developers have been working...